Literature DB >> 28588889

Validation of the Crohn's and Ulcerative Colitis questionnaire in patients with acute severe ulcerative colitis.

Hayley A Hutchings1, Laith Alrubiay1, Alan Watkins1, W-Y Cheung1, Anne C Seagrove1, John G Williams1.   

Abstract

BACKGROUND: The Crohn's and Ulcerative Colitis questionnaire (CUCQ) has previously been validated in patients with mild to moderate Crohn's and ulcerative colitis (UC). The aim of this study was to validate the tool in patients with acute severe UC.
METHODS: We undertook a validation of the CUCQ in patients recruited to the COmparison of iNfliximab and ciclosporin in STeroid Resistant Ulcerative Colitis Trial (CONSTRUCT). We carried out psychometric analysis to examine the underlying dimensions of the scale, internal consistency and construct validity. We carried out stepwise regression to examine which items accounted for the greatest variance in the scale.
RESULTS: We obtained complete data for 270 patients. The internal consistency of the CUCQ was excellent (Cronbach's alpha > 0.8). The CUCQ scores achieved significant correlations with two generic quality of life scales (SF-12 and EQ-5D), demonstrating good construct validity. Stepwise regression identified 16 items that accounted for greater than 95% of the variance of the CUCQ. Only three of the eight items selected for a short form in mild to moderate patients were selected for patients with acute severe UC.
CONCLUSIONS: The CUCQ demonstrated good validity in our sample of acute severe UC patients. Stepwise regression identified potential to shorten the tool, but that different items would be selected compared with less severe patients. If the tool is to be applied across the spectrum of disease it would be more appropriate to use the full 32 items in the scale. Further work to explore test-retest is required in acute patients.

Entities:  

Keywords:  Inflammatory bowel disease; patient-reported outcome measures; quality of life; ulcerative colitis; validation

Year:  2016        PMID: 28588889      PMCID: PMC5446145          DOI: 10.1177/2050640616671627

Source DB:  PubMed          Journal:  United European Gastroenterol J        ISSN: 2050-6406            Impact factor:   4.623


  7 in total

1.  Quality criteria were proposed for measurement properties of health status questionnaires.

Authors:  Caroline B Terwee; Sandra D M Bot; Michael R de Boer; Daniëlle A W M van der Windt; Dirk L Knol; Joost Dekker; Lex M Bouter; Henrica C W de Vet
Journal:  J Clin Epidemiol       Date:  2006-08-24       Impact factor: 6.437

Review 2.  Quality of life of patients with ulcerative colitis: past, present, and future.

Authors:  E Jan Irvine
Journal:  Inflamm Bowel Dis       Date:  2008-04       Impact factor: 5.325

3.  Development of a short questionnaire to assess the quality of life in Crohn's disease and ulcerative colitis.

Authors:  Laith Alrubaiy; Wai-Yee Cheung; Phedra Dodds; Hayley Anne Hutchings; Ian Trevor Russell; Alan Watkins; John Gordon Williams
Journal:  J Crohns Colitis       Date:  2014-10-31       Impact factor: 9.071

4.  Health-related quality of life in inflammatory bowel disease: psychosocial, clinical, socioeconomic, and demographic predictors.

Authors:  Anilga Moradkhani; Linda J Beckman; James H Tabibian
Journal:  J Crohns Colitis       Date:  2012-08-10       Impact factor: 9.071

5.  Comparison Of iNfliximab and ciclosporin in STeroid Resistant Ulcerative Colitis: pragmatic randomised Trial and economic evaluation (CONSTRUCT).

Authors:  John G Williams; M Fasihul Alam; Laith Alrubaiy; Clare Clement; David Cohen; Michelle Grey; Mike Hilton; Hayley A Hutchings; Mirella Longo; Jayne M Morgan; Frances L Rapport; Anne C Seagrove; Alan Watkins
Journal:  Health Technol Assess       Date:  2016-06       Impact factor: 4.014

6.  Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial.

Authors:  David Laharie; Arnaud Bourreille; Julien Branche; Matthieu Allez; Yoram Bouhnik; Jerome Filippi; Frank Zerbib; Guillaume Savoye; Maria Nachury; Jacques Moreau; Jean-Charles Delchier; Jacques Cosnes; Elena Ricart; Olivier Dewit; Antonio Lopez-Sanroman; Jean-Louis Dupas; Franck Carbonnel; Gilles Bommelaer; Benoit Coffin; Xavier Roblin; Gert Van Assche; Maria Esteve; Martti Färkkilä; Javier P Gisbert; Philippe Marteau; Stephane Nahon; Martine de Vos; Denis Franchimont; Jean-Yves Mary; Jean-Frederic Colombel; Marc Lémann
Journal:  Lancet       Date:  2012-10-10       Impact factor: 79.321

7.  Randomised controlled trial. Comparison Of iNfliximab and ciclosporin in STeroid Resistant Ulcerative Colitis: Trial design and protocol (CONSTRUCT).

Authors:  Anne C Seagrove; M Fasihul Alam; Laith Alrubaiy; Wai-Yee Cheung; Clare Clement; David Cohen; Michelle Grey; Mike Hilton; Hayley Hutchings; Jayne Morgan; Frances Rapport; Stephen E Roberts; Daphne Russell; Ian Russell; Linzi Thomas; Kymberley Thorne; Alan Watkins; John G Williams
Journal:  BMJ Open       Date:  2014-04-29       Impact factor: 2.692

  7 in total
  3 in total

1.  Trial summary and protocol for a phase II randomised placebo-controlled double-blinded trial of Interleukin 1 blockade in Acute Severe Colitis: the IASO trial.

Authors:  Martin Geoffrey Thomas; Carrie Bayliss; Simon Bond; Francis Dowling; James Galea; Vipul Jairath; Christopher Lamb; Christopher Probert; Elizabeth Timperley-Preece; Alastair Watson; Lynne Whitehead; John G Williams; Miles Parkes; Arthur Kaser; Tim Raine
Journal:  BMJ Open       Date:  2019-02-15       Impact factor: 2.692

2.  Reliability and Validity of Korean Version of Crohn's and Ulcerative Colitis Questionnaire-8.

Authors:  Sung-Goo Kang; Tae-Geun Gweon; Han Hee Lee; Kang-Moon Lee; Sung Hoon Jung; Sang-Bum Kang
Journal:  Biomed Res Int       Date:  2022-10-07       Impact factor: 3.246

3.  Systematic Review of Development and Content Validity of Patient-reported Outcome Measures in Inflammatory Bowel Disease: Do We Measure What We Measure?

Authors:  Emma M van Andel; Brechtje D M Koopmann; Femke Crouwel; Casper G Noomen; Nanne K H de Boer; Dirk P van Asseldonk; Lidwine B Mokkink
Journal:  J Crohns Colitis       Date:  2020-09-16       Impact factor: 9.071

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.